Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > Insiders Bullish on BioSante Pharma

January 14th, 2008

Insiders Bullish on BioSante Pharma

Abstract:
Over the next year and beyond, LibiGel is expected to be the key value-driver for BioSante, especially now that the Company has achieved clarity on the requirements for FDA approval and has already started the process with just one more Phase 3 efficacy trial due to commence early this year. Key Phase 3 safety data is expected in the latter half of 2009 with an anticipated NDA filing occurring in the first half of 2010 and market launch about one year later. However, shareholders are likely to realize the value of LibiGel much sooner in the form of a lucrative licensing deal or possibly even a buyout based on the product's tremendous sales potential as the first and only FDA-approved treatment for FSD in the US. Both the CEO (Stephen Simes) and the CFO (Phillip Donenberg) of the Company have a solid track record in creating and building value for shareholders with previous success at Unimed and Gynex before they were acquired by Solvay and Savient Pharma, respectively. Also, the recent insider buying suggests that executives and directors at BioSante feel the stock is currently undervalued and is an encouraging sign for investors who may have been waiting on the sidelines for an entry point.

Source:
seekingalpha.com

Bookmark:

Related News Press

News and information

JPK reports on single molecule research at IISER Pune in India using AFM and CellHesion techniques May 21st, 2013

Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013

International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013

Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013

Investments/IPO's/Splits

Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013

Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013

Harris & Harris Group Notes the Sale of a Second D-Wave Quantum Computer May 16th, 2013

Nanometrics Announces Upcoming Investor Events May 14th, 2013

Nanomedicine

How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013

MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013

Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013

Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals

International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013

Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013

Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013

Microneedle-Delivered Nanoparticles Boost Antitumor Vaccines May 20th, 2013